Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.

about

Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.

Item

http://www.wikidata.org/entity/Q48228251

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Randomized phase II trial comp ...... s with recurrent glioblastoma.

@en

Randomized phase II trial comp ...... s with recurrent glioblastoma.

@nl

type

Item

label

Randomized phase II trial comp ...... s with recurrent glioblastoma.

@en

Randomized phase II trial comp ...... s with recurrent glioblastoma.

@nl

prefLabel

Randomized phase II trial comp ...... s with recurrent glioblastoma.

@en

Randomized phase II trial comp ...... s with recurrent glioblastoma.

@nl

P1476

Randomized phase II trial comp ...... ts with recurrent glioblastoma

@en

P2093

A Michotte

http://www.w3.org/2001/XMLSchema#string

C Andre

http://www.w3.org/2001/XMLSchema#string

C Chaskis

http://www.w3.org/2001/XMLSchema#string

F Bouttens

http://www.w3.org/2001/XMLSchema#string

F Van Fraeyenhove

http://www.w3.org/2001/XMLSchema#string

I Salmon

http://www.w3.org/2001/XMLSchema#string

M Le Mercier

http://www.w3.org/2001/XMLSchema#string

N D'Haene

http://www.w3.org/2001/XMLSchema#string

S Du Four

http://www.w3.org/2001/XMLSchema#string

V Verschaeve

http://www.w3.org/2001/XMLSchema#string

P2860

MethyLight: a high-throughput assay to measure DNA methylation

Axitinib for the management of metastatic renal cell carcinoma

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

P2888

s11060-017-2629-z

P304

115-125

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11060-017-2629-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

136

http://www.w3.org/2001/XMLSchema#string

P50

J Duerinck

Anne Rogiers

B Neyns

P577

2017-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28988341

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial